BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33562106)

  • 1. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
    Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
    Oyallon B; Brachet-Botineau M; Logé C; Bonnet P; Souab M; Robert T; Ruchaud S; Bach S; Berthelot P; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Eur J Med Chem; 2018 Jun; 154():101-109. PubMed ID: 29778892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.
    Dao VH; Ourliac-Garnier I; Logé C; McCarthy FO; Bach S; da Silva TG; Denevault-Sabourin C; Thiéfaine J; Baratte B; Robert T; Gouilleux F; Brachet-Botineau M; Bazin MA; Marchand P
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
    Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
    Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
    Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
    J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
    Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
    Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New N-1,N-10-bridged pyrrolo[2,3-a]carbazole-3-carbaldehydes: synthesis and biological activities.
    Giraud F; Bourhis M; Nauton L; Théry V; Herfindal L; Døskeland SO; Anizon F; Moreau P
    Bioorg Chem; 2014 Dec; 57():108-115. PubMed ID: 25305721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, Pim kinase inhibitory potencies and in vitro antiproliferative activities of diversely substituted pyrrolo[2,3-a]carbazoles.
    Akué-Gédu R; Nauton L; Théry V; Bain J; Cohen P; Anizon F; Moreau P
    Bioorg Med Chem; 2010 Sep; 18(18):6865-73. PubMed ID: 20728368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
    Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
    Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
    Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
    Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
    Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
    Bataille CJ; Brennan MB; Byrne S; Davies SG; Durbin M; Fedorov O; Huber KV; Jones AM; Knapp S; Liu G; Nadali A; Quevedo CE; Russell AJ; Walker RG; Westwood R; Wynne GM
    Bioorg Med Chem; 2017 May; 25(9):2657-2665. PubMed ID: 28341403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
    Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
    J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and activities of new indolopyrrolobenzodiazepine derivatives toward acute myeloid leukemia cells.
    Giraud F; Bourhis M; Ebrahimi E; Herfindal L; Choudhury RR; Bjørnstad R; Døskeland SO; Anizon F; Moreau P
    Bioorg Med Chem; 2015 Nov; 23(22):7313-23. PubMed ID: 26526744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
    Quevedo CE; Bataille CJR; Byrne S; Durbin M; Elkins J; Guillermo A; Jones AM; Knapp S; Nadali A; Walker RG; Wilkinson IVL; Wynne GM; Davies SG; Russell AJ
    Bioorg Med Chem; 2020 Nov; 28(22):115724. PubMed ID: 33128909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
    Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
    Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.